XIAO, F. .; XIAO, W. .; LI, X.; LI, R. .; ZHAO, K. . Cost-effectiveness analysis of Trastuzumab Deruxtecan as second-line treatment for HER2- positive advanced breast cancer. Health Decision, [S. l.], v. 2, n. S1, 2024. DOI: 10.54844/hd.2024.0009. Disponível em: https://www.hksmp.com/journals/hd/article/view/655. Acesso em: 2 may. 2025.